Polypharmacy Medication Review / 多重用药审查

Definition

Polypharmacy medication review is the structured reconciliation of every medicine a person uses so that indications, duplication, interactions, doses, timing, formulations, adverse effects, and practical adherence can be assessed together.

Current Synthesis

VOL.224 treats multi-drug safety as more than asking whether two pills “conflict.” 大盆 reports chronic lipid- and urate-lowering medicines plus episodic cold and other drugs, tells new prescribers what he already takes, and worries enough about combinations to invent twenty-minute gaps that turn dosing into a two-hour process. The useful behavior is complete disclosure; the fragile behavior is designing a complex schedule without drug-specific advice.

The episode identifies pharmacists, pharmacy departments, and medication clinics as possible coordination points when several conditions and prescribers make the regimen difficult. Review includes whether a tablet may be split, because modified-release or specially coated formulations can behave differently, and whether simplifying the plan can reduce error without changing therapeutic intent.

Key Claims

• A complete current medicine list is the starting point for interaction and duplication review across conditions and prescribers.
• Safe coordination includes indication, dose, timing, formulation, adverse effects, monitoring, and adherence burden rather than only pairwise interactions.
• Arbitrary time gaps do not reliably prevent interactions and can increase complexity, delay, or missed doses.
• Not every tablet can be safely split; formulation-specific instructions matter.
• Pharmacist-led review can complement prescriber decisions when several medicines or conditions make the regimen hard to manage.

Evidence

• Disclosure and regimen burden: VOL.224 reports that the guest discloses existing medicines but self-created spacing can make the entire sequence take nearly two hours.
• Pharmacy support: VOL.224 describes pharmacy departments or pharmacist clinics as routes for reviewing complex regimens and participating in inpatient consultation.
• Formulation boundary: VOL.224 warns that modified-release or specially coated tablets may not be suitable for splitting.

Counterevidence & Qualifications

The source does not identify every product, strength, formulation, schedule, organ-function constraint, or actual interaction in the guest’s regimen. It therefore cannot show that his medicines should be combined, separated, split, stopped, or continued in a particular way. Access to pharmacist clinics varies, and medication reconciliation does not replace urgent assessment for serious adverse effects or overdose.

What Changed

• Created the concept to distinguish complete medicine disclosure from improvised interaction management.
• Added formulation, simplification, and pharmacist-review branches to the safety model.

Related Concepts

• Medication Interaction Risk - broader food, alcohol, drug, and metabolism interaction category.
• Medication Self-Combination Risk / 药物自行叠加风险 - risk created by adding or stacking medicines without qualified review.
• Chronic Disease Treatment Adherence / 慢病治疗依从性 - continuity challenge that can worsen as regimen burden grows.
• Gout and Urate Long-Term Management / 痛风与尿酸长期管理 - one chronic-treatment branch requiring coordination with other medicines.
• Doctor-Patient Communication - disclosure channel through which medication reconciliation begins.
• Medical Risk Management - weighs therapeutic benefit, adverse effects, interaction probability, and regimen burden.